Skip to content
2000
image of Biological Therapies for Metastatic Colorectal Cancer: Literature Review

Abstract

Colorectal cancer is among the most prevalent and lethal malignancies worldwide. Its initially asymptomatic nature contributes to a high incidence of metastatic cases. Although predominantly diagnosed in older adults, the incidence among younger populations is rising at an alarming rate. Historically, treatment has relied on antineoplastic agents such as 5-fluorouracil, irinotecan, and oxaliplatin. While these agents remain in use, their effectiveness is limited, particularly in metastatic disease, with modest improvements in overall survival and progression-free survival. Moreover, their low target specificity results in significant systemic toxicity. This underscores the urgent need formore selective and less toxic therapeutic strategies, such as monoclonal antibodies. Monoclonal antibodies targeting Vascular Endothelial Growth Factor (VEGF), Epidermal Growth Factor Receptor (EGFR), and immune checkpoints have become integral to the management of metastatic colorectal cancer. Notable examples include bevacizumab (anti-VEGF), cetuximab and panitumumab (anti-EGFR), and the immune checkpoint inhibitors pembrolizumab, nivolumab, and ipilimumab. Their clinical success especially when guided by molecular tumour profiling highlights their contribution to improved patient outcomes. In addition, other targeted therapies distinct from monoclonal antibodies are currently under investigation.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpb/10.2174/0113892010390001251014113106
2026-01-26
2026-01-31

  • From This Site

    /content/journals/cpb/10.2174/0113892010390001251014113106
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Morgan E. Arnold M. Gini A. Lorenzoni V. Cabasag C.J. Laversanne M. Vignat J. Ferlay J. Murphy N. Bray F. Global burden of colorectal cancer in 2020 and 2040: Incidence and mortality estimates from GLOBOCAN. Gut 2023 72 2 338 344 10.1136/gutjnl‑2022‑327736 36604116
    [Google Scholar]
  2. Van Cutsem E. Cervantes A. Nordlinger B. Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014 25 Suppl. 3 iii1 iii9 10.1093/annonc/mdu260 25190710
    [Google Scholar]
  3. Yan C. Shan F. Li Z.Y. [Prevalence of colorectal cancer in 2020: A comparative analysis between China and the world] Zhonghua Zhong Liu Za Zhi 2023 45 3 221 229 36944543
    [Google Scholar]
  4. Kerr D.J. Haller D.G. van de Velde C.J.H. Baumann M., Eds Oxford Textbook of Oncology. 3rd ed United Kingdom Oxford University Press 2016 10.1093/med/9780199656103.001.0001
    [Google Scholar]
  5. Dekker E. Tanis P.J. Vleugels J.L.A. Kasi P.M. Wallace M.B. Colorectal cancer. Lancet 2019 394 10207 1467 1480 10.1016/S0140‑6736(19)32319‑0 31631858
    [Google Scholar]
  6. Schmitt M. Greten F.R. The inflammatory pathogenesis of colorectal cancer. Nat. Rev. Immunol. 2021 21 10 653 667 10.1038/s41577‑021‑00534‑x 33911231
    [Google Scholar]
  7. Nguyen L.H. Goel A. Chung D.C. Pathways of Colorectal Carcinogenesis. Gastroenterology 2020 158 2 291 302 10.1053/j.gastro.2019.08.059 31622622
    [Google Scholar]
  8. La Vecchia S. Sebastián C. Metabolic pathways regulating colorectal cancer initiation and progression. Semin. Cell Dev. Biol. 2020 98 63 70 10.1016/j.semcdb.2019.05.018 31129171
    [Google Scholar]
  9. De’ Angelis G.L.; Bottarelli, L.; Azzoni, C.; De’ Angelis, N.; Leandro, G.; Di Mario, F.; Gaiani, F.; Negri, F. Microsatellite instability in colorectal cancer. Acta Biomed. 2018 89 9-S 97 101 30561401
    [Google Scholar]
  10. East J.E. Atkin W.S. Bateman A.C. Clark S.K. Dolwani S. Ket S.N. Leedham S.J. Phull P.S. Rutter M.D. Shepherd N.A. Tomlinson I. Rees C.J. British society of gastroenterology position statement on serrated polyps in the colon and rectum. Gut 2017 66 7 1181 1196 10.1136/gutjnl‑2017‑314005 28450390
    [Google Scholar]
  11. Xie Y.H. Chen Y.X. Fang J.Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct. Target. Ther. 2020 5 1 22 10.1038/s41392‑020‑0116‑z 32296018
    [Google Scholar]
  12. Guinney J. Dienstmann R. Wang X. de Reyniès A. Schlicker A. Soneson C. Marisa L. Roepman P. Nyamundanda G. Angelino P. Bot B.M. Morris J.S. Simon I.M. Gerster S. Fessler E. De Sousa E. Melo, F.; Missiaglia, E.; Ramay, H.; Barras, D.; Homicsko, K.; Maru, D.; Manyam, G.C.; Broom, B.; Boige, V.; Perez-Villamil, B.; Laderas, T.; Salazar, R.; Gray, J.W.; Hanahan, D.; Tabernero, J.; Bernards, R.; Friend, S.H.; Laurent-Puig, P.; Medema, J.P.; Sadanandam, A.; Wessels, L.; Delorenzi, M.; Kopetz, S.; Vermeulen, L.; Tejpar, S. The consensus molecular subtypes of colorectal cancer. Nat. Med. 2015 21 11 1350 1356 10.1038/nm.3967 26457759
    [Google Scholar]
  13. Gude S.S. Veeravalli R.S. Vejandla B. Gude S.S. Venigalla T. Chintagumpala V. Colorectal cancer diagnostic methods: The present and future. Cureus 2023 15 4 37622 10.7759/cureus.37622 37197135
    [Google Scholar]
  14. Porru M. Pompili L. Caruso C. Biroccio A. Leonetti C. Targeting KRAS in metastatic colorectal cancer: Current strategies and emerging opportunities. J. Exp. Clin. Cancer Res. 2018 37 1 57 10.1186/s13046‑018‑0719‑1 29534749
    [Google Scholar]
  15. Crommelin D.J.A. Sindelar R.D. Meibohm B.,Eds Pharmaceutical Biotechnology. 6th ed Cham Springer International Publishing 2024 10.1007/978‑3‑031‑30023‑3
    [Google Scholar]
  16. Ribecco A.S. Pino M.S. Cipriani G. Marinozzi C. Fioretto L. Molecularly targeted therapy: Toxicity and quality of life considerations in advanced colorectal cancer. Expert Rev. Anticancer Ther. 2013 13 10 1181 1191 10.1586/14737140.2013.837667 24134420
    [Google Scholar]
  17. Venook A.P. Niedzwiecki D. Lenz H.J. Innocenti F. Fruth B. Meyerhardt J.A. Schrag D. Greene C. O’Neil B.H. Atkins J.N. Berry S. Polite B.N. O’Reilly E.M. Goldberg R.M. Hochster H.S. Schilsky R.L. Bertagnolli M.M. El-Khoueiry A.B. Watson P. Benson A.B. Mulkerin D.L. Mayer R.J. Blanke C. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer. JAMA 2017 317 23 2392 2401 10.1001/jama.2017.7105 28632865
    [Google Scholar]
  18. Saharinen P. Eklund L. Pulkki K. Bono P. Alitalo K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol. Med. 2011 17 7 347 362 10.1016/j.molmed.2011.01.015 21481637
    [Google Scholar]
  19. Mamer S.B. Palasz A.A. Imoukhuede P.I. Mapping tyrosine kinase receptor dimerization to receptor expression and ligand affinities. Processes 2019 7 5 288 10.3390/pr7050288
    [Google Scholar]
  20. Ferrara N. Gerber H.P. LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003 9 6 669 676 10.1038/nm0603‑669 12778165
    [Google Scholar]
  21. Dakowicz D. Zajkowska M. Mroczko B. Relationship between VEGF family members, their receptors and cell death in the neoplastic transformation of colorectal cancer. Int. J. Mol. Sci. 2022 23 6 3375 10.3390/ijms23063375 35328794
    [Google Scholar]
  22. Rutkowski P. Mandalà M.,Eds New Therapies in Advanced Cutaneous Malignancies. Cham Springer International Publishing 2021 10.1007/978‑3‑030‑64009‑5
    [Google Scholar]
  23. Shehzad A. Cell. Signaling. 1st ed Boca Raton CRC Press 2025 10.1201/9781003594901
    [Google Scholar]
  24. Lee Y.J. Karl D.L. Maduekwe U.N. Rothrock C. Ryeom S. D’Amore P.A. Yoon S.S. RETRACTED: Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment. Cancer Res. 2010 70 21 8357 8367 10.1158/0008‑5472.CAN‑10‑1138 20978198
    [Google Scholar]
  25. Lopez A. Harada K. Vasilakopoulou M. Shanbhag N. Ajani J.A. Targeting angiogenesis in colorectal carcinoma. Drugs 2019 79 1 63 74 10.1007/s40265‑018‑1037‑9 30617958
    [Google Scholar]
  26. Moret E. Ambresin A. Gianniou C. Bijon J. Besse-Hayat C. Bogiatzi S. Hohl D. Spertini F. Mantel I. Non-immediate drug hypersensitivity reactions secondary to intravitreal anti-vascular endothelial growth factors. Graefes Arch. Clin. Exp. Ophthalmol. 2022 260 3 1005 1014 10.1007/s00417‑021‑05353‑3 34529134
    [Google Scholar]
  27. European medicines agency 2020 Available from: https://www.ema.europa.eu/en/documents/productinformation/avastin-epar-product-information_en.pdf
  28. Colorectal metastatic FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) and bevacizumab 2024 Available from: https://www.eviq.org.au/medicaloncology/colorectal/metastatic/986-colorectalmetastatic-folfox6-modified-fluo
  29. Colorectal metastatic FOLFIRI (modified) (fluorouracil leucovorinirinotecan) and bevacizumab 2024 Available from: https://www.eviq.org.au/medicaloncology/colorectal/metastatic/89-colorectalmetastatic-folfiri-modified-fluor
  30. Saltz L.B. Clarke S. Díaz-Rubio E. Scheithauer W. Figer A. Wong R. Koski S. Lichinitser M. Yang T.S. Rivera F. Couture F. Sirzén F. Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J. Clin. Oncol. 2008 26 12 2013 2019 10.1200/JCO.2007.14.9930 18421054
    [Google Scholar]
  31. Scheithauer W. Current treatment benefits in advanced colorectal cancer. Lancet Oncol. 2007 8 10 857 859 10.1016/S1470‑2045(07)70290‑5 17913652
    [Google Scholar]
  32. Jenab-Wolcott J. Giantonio B. The continuum of care in chemotherapy approach to metastatic colorectal cancer. Curr. Colorectal Cancer Rep. 2013 9 3 230 241 10.1007/s11888‑013‑0178‑1
    [Google Scholar]
  33. Tang W. Ren L. Liu T. Ye Q. Wei Y. He G. Lin Q. Wang X. Wang M. Liang F. Cui Y. Xu J. Bevacizumab plus mFOLFOX6 versus mFOLFOX6 alone as first-line treatment for RAS mutant unresectable colorectal liver-limited metastases: The become randomized controlled trial. J. Clin. Oncol. 2020 38 27 3175 3184 10.1200/JCO.20.00174 32749938
    [Google Scholar]
  34. Hurwitz H. Fehrenbacher L. Novotny W. Cartwright T. Hainsworth J. Heim W. Berlin J. Baron A. Griffing S. Holmgren E. Ferrara N. Fyfe G. Rogers B. Ross R. Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004 350 23 2335 2342 10.1056/NEJMoa032691 15175435
    [Google Scholar]
  35. Falcone A. Ricci S. Brunetti I. Pfanner E. Allegrini G. Barbara C. Crinò L. Benedetti G. Evangelista W. Fanchini L. Cortesi E. Picone V. Vitello S. Chiara S. Granetto C. Porcile G. Fioretto L. Orlandini C. Andreuccetti M. Masi G. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 2007 25 13 1670 1676 10.1200/JCO.2006.09.0928 17470860
    [Google Scholar]
  36. Davis D.W. Herbst R.S. Abbruzzese J.L.,Eds Antiangiogenic Cancer Therapy. 1st ed Boca Raton, Florida CRC Press 2007 10.1201/9781420004298
    [Google Scholar]
  37. Summary of product characteristics: Zaltrap 25 mg/ml concentrate for solution for infusion 2024 Available from: https://www.ema.europa.eu/en/documents/productinformation/zaltrap-epar-product-information_en.pdf
  38. Morgado S. Silva M. Fonseca O. Roque F. Morgado M. Targeted therapy for metastatic colorectal cancer: What do we currently have in clinical practice? Drugs Ther. Perspect. 2022 38 5 222 234 10.1007/s40267‑022‑00915‑9
    [Google Scholar]
  39. Van Cutsem E. Tabernero J. Lakomy R. Prenen H. Prausová J. Macarulla T. Ruff P. van Hazel G.A. Moiseyenko V. Ferry D. McKendrick J. Polikoff J. Tellier A. Castan R. Allegra C. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 2012 30 28 3499 3506 10.1200/JCO.2012.42.8201 22949147
    [Google Scholar]
  40. Folprecht G. Pericay C. Saunders M.P. Thomas A. Lopez Lopez R. Roh J.K. Chistyakov V. Höhler T. Kim J.S. Hofheinz R.D. Ackland S.P. Swinson D. Kopp M. Udovitsa D. Hall M. Iveson T. Vogel A. Zalcberg J.R. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: The AFFIRM study. Ann. Oncol. 2016 27 7 1273 1279 10.1093/annonc/mdw176 27091810
    [Google Scholar]
  41. National comprehensive cancer network: Clinical practice guidelines in oncology (NCCN Guidelines®): Colon cancer 2024 Available from: https://www.nccn.org/professionals/physician_gls/pd f/colon.pdf
  42. Summary of product characteristics: Cyramza 10 mg/ml concentrate for solution for infusion 2024Available from: https://www.ema.europa.eu/en/documents/productinformation/cyramza-epar-productinformation_en.pdf
  43. Tabernero J. Yoshino T. Cohn A.L. Obermannova R. Bodoky G. Garcia-Carbonero R. Ciuleanu T.E. Portnoy D.C. Van Cutsem E. Grothey A. Prausová J. Garcia-Alfonso P. Yamazaki K. Clingan P.R. Lonardi S. Kim T.W. Simms L. Chang S.C. Nasroulah F. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015 16 5 499 508 10.1016/S1470‑2045(15)70127‑0 25877855
    [Google Scholar]
  44. Wilke H. Muro K. Van Cutsem E. Oh S.C. Bodoky G. Shimada Y. Hironaka S. Sugimoto N. Lipatov O. Kim T.Y. Cunningham D. Rougier P. Komatsu Y. Ajani J. Emig M. Carlesi R. Ferry D. Chandrawansa K. Schwartz J.D. Ohtsu A. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol. 2014 15 11 1224 1235 10.1016/S1470‑2045(14)70420‑6 25240821
    [Google Scholar]
  45. Garon E.B. Ciuleanu T.E. Arrieta O. Prabhash K. Syrigos K.N. Goksel T. Park K. Gorbunova V. Kowalyszyn R.D. Pikiel J. Czyzewicz G. Orlov S.V. Lewanski C.R. Thomas M. Bidoli P. Dakhil S. Gans S. Kim J.H. Grigorescu A. Karaseva N. Reck M. Cappuzzo F. Alexandris E. Sashegyi A. Yurasov S. Pérol M. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial. Lancet 2014 384 9944 665 673 10.1016/S0140‑6736(14)60845‑X 24933332
    [Google Scholar]
  46. Arteaga C.L. Engelman J.A. ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014 25 3 282 303 10.1016/j.ccr.2014.02.025 24651011
    [Google Scholar]
  47. Roskoski R. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol. Res. 2019 139 395 411 10.1016/j.phrs.2018.11.014 30500458
    [Google Scholar]
  48. Wang Z. Erb B. Receptors and cancer. Methods Mol. Biol. 2017 1652 3 35 10.1007/978‑1‑4939‑7219‑7_1 28791631
    [Google Scholar]
  49. Tan C. Du X. KRAS mutation testing in metastatic colorectal cancer. World J. Gastroenterol. 2012 18 37 5171 5180 23066310
    [Google Scholar]
  50. Vigil D. Cherfils J. Rossman K.L. Der C.J. Ras superfamily GEFs and GAPs: Validated and tractable targets for cancer therapy? Nat. Rev. Cancer 2010 10 12 842 857 10.1038/nrc2960 21102635
    [Google Scholar]
  51. Ros J. Saoudi N. Baraibar I. Salva F. Tabernero J. Elez E. Encorafenib plus cetuximab for the treatment of BRAF-V600E -mutated metastatic colorectal cancer. Therap. Adv. Gastroenterol. 2022 15 17562848221110644 10.1177/17562848221110644 35812780
    [Google Scholar]
  52. Demin O. Smirnov S. Diakonova A. Roskoshnaia A. Bajaj G. Adams H. Gupta M. Thalhauser C. 1280Modeling of direct (EGFR- based) and ADCC cytotoxic effect of Cetuximab on the basis of literature available in vitro data. In: Regular and Young Investigator Award Abstracts. United Kingdom BMJ Publishing Group Ltd 2023 A1420 A1420 10.1136/jitc‑2023‑SITC2023.1280
    [Google Scholar]
  53. Summary of product characteristics: Erbitux 5 mg/mL solution for infusion 2024 Available from: https://www.ema.europa.eu/en/documents/productinformation/cyramza-epar-productinformation_en.pdf
  54. Bokemeyer C. Bondarenko I. Makhson A. Hartmann J.T. Aparicio J. de Braud F. Donea S. Ludwig H. Schuch G. Stroh C. Loos A.H. Zubel A. Koralewski P. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 2009 27 5 663 671 10.1200/JCO.2008.20.8397 19114683
    [Google Scholar]
  55. Koopman M. Antonini N.F. Douma J. Wals J. Honkoop A.H. Erdkamp F.L.G. de Jong R.S. Rodenburg C.J. Vreugdenhil G. Loosveld O.J.L. van Bochove A. Sinnige H.A.M. Creemers G.J.M. Tesselaar M.E.T. Slee P.H.T.J. Werter M.J.B.P. Mol L. Dalesio O. Punt C.J.A. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial. Lancet 2007 370 9582 135 142 10.1016/S0140‑6736(07)61086‑1 17630036
    [Google Scholar]
  56. Bokemeyer C. Bondarenko I. Hartmann J.T. de Braud F. Schuch G. Zubel A. Celik I. Schlichting M. Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann. Oncol. 2011 22 7 1535 1546 10.1093/annonc/mdq632 21228335
    [Google Scholar]
  57. Van Cutsem E. Köhne C.H. Hitre E. Zaluski J. Chang C. C.R.; Makhson, A.; D’Haens, G.; Pintér, T.; Lim, R.; Bodoky, G.; Roh, J.K.; Folprecht, G.; Ruff, P.; Stroh, C.; Tejpar, S.; Schlichting, M.; Nippgen, J.; Rougier, P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 2009 360 14 1408 1417 10.1056/NEJMoa0805019 19339720
    [Google Scholar]
  58. Sargent D.J. Sargent D.J. Nair S. Mahoney M.R. Mooney M. Thibodeau S.N. Smyrk T.C. Sinicrope F.A. Chan E. Gill S. Kahlenberg M.S. Shields A.F. Quesenberry J.T. Webb T.A. Farr G.H. Pockaj B.A. Grothey A. Goldberg R.M. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial. JAMA 2012 307 13 1383 1393 10.1001/jama.2012.385 22474202
    [Google Scholar]
  59. Ye L.C. Liu T.S. Ren L. Wei Y. Zhu D.X. Zai S.Y. Ye Q.H. Yu Y. Xu B. Qin X.Y. Xu J. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J. Clin. Oncol. 2013 31 16 1931 1938 10.1200/JCO.2012.44.8308 23569301
    [Google Scholar]
  60. Jonker D.J. O’Callaghan C.J. Karapetis C.S. Zalcberg J.R. Tu D. Au H.J. Berry S.R. Krahn M. Price T. Simes R.J. Tebbutt N.C. van Hazel G. Wierzbicki R. Langer C. Moore M.J. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 2007 357 20 2040 2048 10.1056/NEJMoa071834 18003960
    [Google Scholar]
  61. Sood A. Saraswat N. Kumar D. Verma R. Sushil K. Clinical profile of cutaneous adverse effects of epidermal growth factor receptor inhibitors: A prospective observational study of 76 cases. Indian Dermatol. Online J. 2019 10 3 251 255 10.4103/idoj.IDOJ_325_18 31149566
    [Google Scholar]
  62. Gürsoy P. Çakar B. Almuradova E. Karateke M. Doğanavşargil B. Sezak M. Harman M. Karabulut B. The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience. J. Chemother. 2021 33 3 180 186 10.1080/1120009X.2020.1861531 33349195
    [Google Scholar]
  63. Van Cutsem E. Peeters M. Siena S. Humblet Y. Hendlisz A. Neyns B. Canon J.L. Van Laethem J.L. Maurel J. Richardson G. Wolf M. Amado R.G. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 2007 25 13 1658 1664 10.1200/JCO.2006.08.1620 17470858
    [Google Scholar]
  64. Douillard J.Y. Siena S. Cassidy J. Tabernero J. Burkes R. Barugel M. Humblet Y. Bodoky G. Cunningham D. Jassem J. Rivera F. Kocákova I. Ruff P. Błasińska-Morawiec M. Šmakal M. Canon J.L. Rother M. Oliner K.S. Wolf M. Gansert J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J. Clin. Oncol. 2010 28 31 4697 4705 10.1200/JCO.2009.27.4860 20921465
    [Google Scholar]
  65. Douillard J.Y. Oliner K.S. Siena S. Tabernero J. Burkes R. Barugel M. Humblet Y. Bodoky G. Cunningham D. Jassem J. Rivera F. Kocákova I. Ruff P. Błasińska-Morawiec M. Šmakal M. Canon J.L. Rother M. Williams R. Rong A. Wiezorek J. Sidhu R. Patterson S.D. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 2013 369 11 1023 1034 10.1056/NEJMoa1305275 24024839
    [Google Scholar]
  66. Wang Y. Jones J.C. Kipp B.R. Grothey A. Activity of EGFR antibody in non-V600 BRAF mutant metastatic colorectal cancer. Ann. Oncol. 2019 30 1 147 149 10.1093/annonc/mdy477 30364934
    [Google Scholar]
  67. Yaeger R. Kotani D. Mondaca S. Parikh A.R. Bando H. Van Seventer E.E. Taniguchi H. Zhao H. Thant C.N. de Stanchina E. Rosen N. Corcoran R.B. Yoshino T. Yao Z. Ebi H. Response to anti-EGFR therapy in patients with BRAF non-V600–mutant metastatic colorectal cancer. Clin. Cancer Res. 2019 25 23 7089 7097 10.1158/1078‑0432.CCR‑19‑2004 31515458
    [Google Scholar]
  68. Resumo das características do medicamento vectibix. 2017 Available from: https://www.ema.europa.eu/en/documents/productinformation/vectibix-epar-productinformation_pt.pdf
  69. Carrato A. Abad A. Massuti B. Grávalos C. Escudero P. Longo-Muñoz F. Manzano J.L. Gómez A. Safont M.J. Gallego J. García-Paredes B. Pericay C. Dueñas R. Rivera F. Losa F. Valladares-Ayerbes M. González E. Aranda E. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). Eur. J. Cancer 2017 81 191 202 10.1016/j.ejca.2017.04.024 28633089
    [Google Scholar]
  70. Geredeli C. Yasar N. FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer. World J. Surg. Oncol. 2018 16 1 67 10.1186/s12957‑018‑1359‑9 29587749
    [Google Scholar]
  71. Blows W.T. The Biological Basis of Cancer. 2nd ed London Routledge 2025 10.4324/9781003389125
    [Google Scholar]
  72. Pauken K.E. Wherry E.J. Overcoming T. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015 36 4 265 276 10.1016/j.it.2015.02.008 25797516
    [Google Scholar]
  73. Tay R.E. Richardson E.K. Toh H.C. Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms. Cancer Gene Ther. 2021 28 1-2 5 17 10.1038/s41417‑020‑0183‑x 32457487
    [Google Scholar]
  74. Black M. Barsoum I.B. Truesdell P. Cotechini T. Macdonald-Goodfellow S.K. Petroff M. Siemens D.R. Koti M. Craig A.W.B. Graham C.H. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. Oncotarget 2016 7 9 10557 10567 10.18632/oncotarget.7235 26859684
    [Google Scholar]
  75. Akbay E.A. Koyama S. Carretero J. Altabef A. Tchaicha J.H. Christensen C.L. Mikse O.R. Cherniack A.D. Beauchamp E.M. Pugh T.J. Wilkerson M.D. Fecci P.E. Butaney M. Reibel J.B. Soucheray M. Cohoon T.J. Janne P.A. Meyerson M. Hayes D.N. Shapiro G.I. Shimamura T. Sholl L.M. Rodig S.J. Freeman G.J. Hammerman P.S. Dranoff G. Wong K.K. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013 3 12 1355 1363 10.1158/2159‑8290.CD‑13‑0310 24078774
    [Google Scholar]
  76. Rudd C.E. Taylor A. Schneider H. CD28 and CTLA‐4 coreceptor expression and signal transduction. Immunol. Rev. 2009 229 1 12 26 10.1111/j.1600‑065X.2009.00770.x 19426212
    [Google Scholar]
  77. André T. Cohen R. Salem M.E. Immune checkpoint blockade therapy in patients with colorectal cancer harboring microsatellite instability/mismatch repair deficiency in 2022. Am. Soc. Clin. Oncol. Educ. Book 2022 42 42 233 241 10.1200/EDBK_349557 35471834
    [Google Scholar]
  78. Cohen R. Colle R. Pudlarz T. Heran M. Duval A. Svrcek M. André T. Immune checkpoint inhibition in metastatic colorectal cancer harboring microsatellite instability or mismatch repair deficiency. Cancers 2021 13 5 1149 10.3390/cancers13051149 33800202
    [Google Scholar]
  79. Herbener P. Schönfeld K. König M. Germer M. Przyborski J.M. Bernöster K. Schüttrumpf J. Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate. PLoS One 2018 13 4 0195823 10.1371/journal.pone.0195823 29672587
    [Google Scholar]
  80. Diaz L.A. Shiu K.K. Kim T.W. Jensen B.V. Jensen L.H. Punt C. Smith D. Garcia-Carbonero R. Benavides M. Gibbs P. de la Fourchardiere C. Rivera F. Elez E. Le D.T. Yoshino T. Zhong W.Y. Fogelman D. Marinello P. Andre T. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): Final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022 23 5 659 670 10.1016/S1470‑2045(22)00197‑8 35427471
    [Google Scholar]
  81. Le D.T. Diaz L.A. Kim T.W. Van Cutsem E. Geva R. Jäger D. Hara H. Burge M. O’Neil B.H. Kavan P. Yoshino T. Guimbaud R. Taniguchi H. Élez E. Al-Batran S.E. Boland P.M. Cui Y. Leconte P. Marinello P. André T. Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: Final analysis of KEYNOTE-164. Eur. J. Cancer 2023 186 185 195 10.1016/j.ejca.2023.02.016 37141828
    [Google Scholar]
  82. Yin Q. Wu L. Han L. Zheng X. Tong R. Li L. Bai L. Bian Y. Immune-related adverse events of immune checkpoint inhibitors: A review. Front. Immunol. 2023 14 1167975 10.3389/fimmu.2023.1167975 37304306
    [Google Scholar]
  83. Rajha E. Chaftari P. Kamal M. Maamari J. Chaftari C. Yeung S.C.J. Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy. Gastroenterol. Rep. (Oxf.) 2020 8 1 25 30 10.1093/gastro/goz065 32104583
    [Google Scholar]
  84. Summary of product characteristics: Yervoy 5 mg/mL concentrate for solution for infusion. 2024Available from: https://www.ema.europa.eu/en/documents/productinformation/yervoy-epar-product-information_en.pdf
  85. Summary of product characteristics: Opdivo 10 mg/mL concentrate for solution for infusion. 2024Available from: https://www.ema.europa.eu/en/documents/productinformation/opdivo-epar-product-information_en.pdf
  86. Smith K.M. Desai J. Nivolumab for the treatment of colorectal cancer. Expert Rev. Anticancer Ther. 2018 18 7 611 618 10.1080/14737140.2018.1480942 29792730
    [Google Scholar]
  87. Brahmer J.R. Drake C.G. Wollner I. Powderly J.D. Picus J. Sharfman W.H. Stankevich E. Pons A. Salay T.M. McMiller T.L. Gilson M.M. Wang C. Selby M. Taube J.M. Anders R. Chen L. Korman A.J. Pardoll D.M. Lowy I. Topalian S.L. Phase I. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 2010 28 19 3167 3175 10.1200/JCO.2009.26.7609 20516446
    [Google Scholar]
  88. Overman M.J. McDermott R. Leach J.L. Lonardi S. Lenz H.J. Morse M.A. Desai J. Hill A. Axelson M. Moss R.A. Goldberg M.V. Cao Z.A. Ledeine J.M. Maglinte G.A. Kopetz S. André T. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. Lancet Oncol. 2017 18 9 1182 1191 10.1016/S1470‑2045(17)30422‑9 28734759
    [Google Scholar]
  89. Xu Y. Hezam K. Ali M.G. Wang Y. Zhang J. The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: A meta-analysis. Immunopharmacol. Immunotoxicol. 2021 43 3 386 394 10.1080/08923973.2021.1924195 34014122
    [Google Scholar]
  90. Das R. Verma R. Sznol M. Boddupalli C.S. Gettinger S.N. Kluger H. Callahan M. Wolchok J.D. Halaban R. Dhodapkar M.V. Dhodapkar K.M. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J. Immunol. 2015 194 3 950 959 10.4049/jimmunol.1401686 25539810
    [Google Scholar]
  91. Lenz H.J.J. Van Cutsem E. Limon M.L. Wong K.Y. Hendlisz A. Aglietta M. Garcia-Alfonso P. Neyns B. Luppi G. Cardin D. Dragovich T. Shah U. Atasoy A. Postema R. Boyd Z. Ledeine J.M. Overman M. Lonardi S. Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Ann. Oncol. 2018 29 viii714 10.1093/annonc/mdy424.019
    [Google Scholar]
  92. Overman M.J. Lonardi S. Wong K.Y.M. Lenz H.J. Gelsomino F. Aglietta M. Morse M.A. Van Cutsem E. McDermott R. Hill A. Sawyer M.B. Hendlisz A. Neyns B. Svrcek M. Moss R.A. Ledeine J.M. Cao Z.A. Kamble S. Kopetz S. André T. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer. J. Clin. Oncol. 2018 36 8 773 779 10.1200/JCO.2017.76.9901 29355075
    [Google Scholar]
  93. Wright J.J. Powers A.C. Johnson D.B. Endocrine toxicities of immune checkpoint inhibitors. Nat. Rev. Endocrinol. 2021 17 7 389 399 10.1038/s41574‑021‑00484‑3 33875857
    [Google Scholar]
  94. Dzunic M. Petkovic I. Cvetanovic A. Vrbic S. Pejcic I. Current and future targets and therapies in metastatic colorectal cancer. JBUON 2019 24 5 1785 1792 31786838
    [Google Scholar]
  95. Tang Y.L. Li D.D. Duan J.Y. Sheng L.M. Wang X. Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments. World J. Gastroenterol. 2023 29 6 926 948 10.3748/wjg.v29.i6.926 36844139
    [Google Scholar]
  96. Yuan J. Li J. Gao C. Jiang C. Xiang Z. Wu J. Immunotherapies catering to the unmet medical need of cold colorectal cancer. Front. Immunol. 2022 13 1022190 10.3389/fimmu.2022.1022190 36275766
    [Google Scholar]
  97. Fan A. Wang B. Wang X. Nie Y. Fan D. Zhao X. Lu Y. Immunotherapy in colorectal cancer: Current achievements and future perspective. Int. J. Biol. Sci. 2021 17 14 3837 3849 10.7150/ijbs.64077 34671202
    [Google Scholar]
  98. Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update. Pharmacol. Res. 2024 200 107059 10.1016/j.phrs.2024.107059 38216005
    [Google Scholar]
  99. Ríos-Hoyo A. Monzonís X. Vidal J. Linares J. Montagut C. Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: A long and winding road. Front. Pharmacol. 2024 15 1398419 10.3389/fphar.2024.1398419 38711991
    [Google Scholar]
  100. Gaya A. Tse V. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat. Rev. 2012 38 5 484 493 10.1016/j.ctrv.2011.12.008 22264850
    [Google Scholar]
  101. Summary of product characteristics: Keytruda, 25 mg/mL concentrate for solution for infusion 2024 Available from: https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf
  102. Summary of product characteristics: Stivarga. 2024 Available from:https://www.ema.europa.eu/en/documents/product-information/stivarga-epar-product-information_pt.pdf
  103. Grothey A. Cutsem E.V. Sobrero A. Siena S. Falcone A. Ychou M. Humblet Y. Bouché O. Mineur L. Barone C. Adenis A. Tabernero J. Yoshino T. Lenz H.J. Goldberg R.M. Sargent D.J. Cihon F. Cupit L. Wagner A. Laurent D. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013 381 9863 303 312 10.1016/S0140‑6736(12)61900‑X 23177514
    [Google Scholar]
  104. Li J. Qin S. Xu R. Yau T.C.C. Ma B. Pan H. Xu J. Bai Y. Chi Y. Wang L. Yeh K.H. Bi F. Cheng Y. Le A.T. Lin J.K. Liu T. Ma D. Kappeler C. Kalmus J. Kim T.W. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015 16 6 619 629 10.1016/S1470‑2045(15)70156‑7 25981818
    [Google Scholar]
  105. Summary of product characteristics: Braftovi. 2021 Available from: https://www.ema.europa.eu/en/documents/productinformation/braftovi-epar-productinformation_pt.pdf
  106. Kopetz S. Grothey A. Yaeger R. Van Cutsem E. Desai J. Yoshino T. Wasan H. Ciardiello F. Loupakis F. Hong Y.S. Steeghs N. Guren T.K. Arkenau H.T. Garcia-Alfonso P. Pfeiffer P. Orlov S. Lonardi S. Elez E. Kim T.W. Schellens J.H.M. Guo C. Krishnan A. Dekervel J. Morris V. Calvo Ferrandiz A. Tarpgaard L.S. Braun M. Gollerkeri A. Keir C. Maharry K. Pickard M. Christy-Bittel J. Anderson L. Sandor V. Tabernero J. Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer. N. Engl. J. Med. 2019 381 17 1632 1643 10.1056/NEJMoa1908075 31566309
    [Google Scholar]
  107. Mitani S. Taniguchi H. Sugiyama K. Masuishi T. Honda K. Narita Y. Kadowaki S. Ura T. Ando M. Tajika M. Yatabe Y. Muro K. The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation. Ther. Adv. Med. Oncol. 2019 11 1758835918820298 10.1177/1758835918820298 30719102
    [Google Scholar]
  108. Peeters M. Oliner K.S. Price T.J. Cervantes A. Sobrero A.F. Ducreux M. Hotko Y. André T. Chan E. Lordick F. Punt C.J.A. Strickland A.H. Wilson G. Ciuleanu T.E. Roman L. Van Cutsem E. He P. Yu H. Koukakis R. Terwey J.H. Jung A.S. Sidhu R. Patterson S.D. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with folfiri compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin. Cancer Res. 2015 21 24 5469 5479 10.1158/1078‑0432.CCR‑15‑0526 26341920
    [Google Scholar]
  109. Rosen R.D. Sapra A. TNM classification. 2023Available from: https://www.ncbi.nlm.nih.gov/books/NBK553187//
    [Google Scholar]
  110. Anitei M.G. Zeitoun G. Mlecnik B. Marliot F. Haicheur N. Todosi A.M. Kirilovsky A. Lagorce C. Bindea G. Ferariu D. Danciu M. Bruneval P. Scripcariu V. Chevallier J.M. Zinzindohoué F. Berger A. Galon J. Pagès F. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin. Cancer Res. 2014 20 7 1891 1899 10.1158/1078‑0432.CCR‑13‑2830 24691640
    [Google Scholar]
  111. Hidalgo M. Martinez-Garcia M. Le Tourneau C. Massard C. Garralda E. Boni V. Taus A. Albanell J. Sablin M.P. Alt M. Bahleda R. Varga A. Boetsch C. Franjkovic I. Heil F. Lahr A. Lechner K. Morel A. Nayak T. Rossomanno S. Smart K. Stubenrauch K. Krieter O. First-in-human phase I study of single-agent vanucizumab, A first-in-class bispecific anti-angiopoietin-2/anti-vegf-a antibody, in adult patients with advanced solid tumors. Clin. Cancer Res. 2018 24 7 1536 1545 10.1158/1078‑0432.CCR‑17‑1588 29217526
    [Google Scholar]
  112. Hong D.S. Fakih M.G. Strickler J.H. Desai J. Durm G.A. Shapiro G.I. Falchook G.S. Price T.J. Sacher A. Denlinger C.S. Bang Y.J. Dy G.K. Krauss J.C. Kuboki Y. Kuo J.C. Coveler A.L. Park K. Kim T.W. Barlesi F. Munster P.N. Ramalingam S.S. Burns T.F. Meric-Bernstam F. Henary H. Ngang J. Ngarmchamnanrith G. Kim J. Houk B.E. Canon J. Lipford J.R. Friberg G. Lito P. Govindan R. Li B.T. KRAS G12C inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med. 2020 383 13 1207 1217 10.1056/NEJMoa1917239 32955176
    [Google Scholar]
  113. Fakih M.G. Salvatore L. Esaki T. Modest D.P. Lopez-Bravo D.P. Taieb J. Karamouzis M.V. Ruiz-Garcia E. Kim T.W. Kuboki Y. Meriggi F. Cunningham D. Yeh K.H. Chan E. Chao J. Saportas Y. Tran Q. Cremolini C. Pietrantonio F. Sotorasib plus panitumumab in refractory colorectal cancer with mutated KRAS G12C. N. Engl. J. Med. 2023 389 23 2125 2139 10.1056/NEJMoa2308795 37870968
    [Google Scholar]
  114. Yaeger R. Uboha N.V. Pelster M.S. Bekaii-Saab T.S. Barve M. Saltzman J. Sabari J.K. Peguero J.A. Paulson A.S. Jänne P.A. Cruz-Correa M. Anderes K. Velastegui K. Yan X. Der-Torossian H. Klempner S.J. Kopetz S.E. Efficacy and safety of adagrasib plus cetuximab in patients with KRAS G12C-mutated metastatic colorectal cancer. Cancer Discov. 2024 14 6 982 993 10.1158/2159‑8290.CD‑24‑0217 38587856
    [Google Scholar]
  115. Knox J.E. Jiang J. Burnett G.L. Liu Y. Weller C.E. Wang Z. McDowell L. Steele S.L. Chin S. Chou K.J. Wang F. Zhong M. Koltun E.S. Wildes D. Singh M. Gill A.L. Smith J.A. in: RM036, a First-in-class, orally-bioavailable, tricomplex covalent krasg12d(on) inhibitor, drives profound anti-tumor activity in KRASG12D mutant tumor models, proceeding of the american association for cancer research, annual meeting new orleans. Cancer Res. 2022 82 12 3596 3596 10.1158/1538‑7445.AM2022‑3596
    [Google Scholar]
  116. Wang X. Allen S. Blake J.F. Bowcut V. Briere D.M. Calinisan A. Dahlke J.R. Fell J.B. Fischer J.P. Gunn R.J. Hallin J. Laguer J. Lawson J.D. Medwid J. Newhouse B. Nguyen P. O’Leary J.M. Olson P. Pajk S. Rahbaek L. Rodriguez M. Smith C.R. Tang T.P. Thomas N.C. Vanderpool D. Vigers G.P. Christensen J.G. Marx M.A. Identification of MRTX1133, a noncovalent, potent, and selective KRAS G12D inhibitor. J. Med. Chem. 2022 65 4 3123 3133 10.1021/acs.jmedchem.1c01688 34889605
    [Google Scholar]
  117. Kanikarla Marie P. Haymaker C. Parra E.R. Kim Y.U. Lazcano R. Gite S. Lorenzini D. Wistuba I.I. Tidwell R.S.S. Song X. Foo W.C. Maru D.M. Chun Y.S. Futreal A. Kee B. Menter D. Solis L. Tzeng C.W. Parseghian C. Raghav K. Morris V. Chang C.C. Jenq R. Tam A. Bernatchez C. Kopetz S. Vauthey J.N. Overman M.J. Pilot clinical trial of perioperative durvalumab and tremelimumab in the treatment of resectable colorectal cancer liver metastases. Clin. Cancer Res. 2021 27 11 3039 3049 10.1158/1078‑0432.CCR‑21‑0163 33811152
    [Google Scholar]
  118. André T. Berton D. Curigliano G. Sabatier R. Tinker A.V. Oaknin A. Ellard S. de Braud F. Arkenau H.T. Trigo J. Gravina A. Kristeleit R. Moreno V. Abdeddaim C. Vano Y.A. Samouëlian V. Miller R. Boni V. Torres A.A. Gilbert L. Brown J. Dewal N. Dabrowski C. Antony G. Zografos E. Veneris J. Banerjee S. Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors. JAMA Netw. Open 2023 6 11 2341165 10.1001/jamanetworkopen.2023.41165 37917058
    [Google Scholar]
  119. García-Martínez J.M. Wang S. Weishaeupl C. Wernitznig A. Chetta P. Pinto C. Ho J. Dutcher D. Gorman P.N. Kroe-Barrett R. Rinnenthal J. Giragossian C. Impagnatiello M.A. Tirapu I. Hilberg F. Kraut N. Pearson M. Kuenkele K.P. Selective tumor cell apoptosis and tumor regression in cdh17-positive colorectal cancer models using BI 905711, a novel liver-sparing TRAILR2 agonist. Mol. Cancer Ther. 2021 20 1 96 108 10.1158/1535‑7163.MCT‑20‑0253 33037135
    [Google Scholar]
  120. Mathur D. Root A.R. Bugaj-Gaweda B. Bisulco S. Tan X. Fang W. Kearney J.C. Lucas J. Guffroy M. Golas J. Rohde C.M. Stevens C. Kamperschroer C. Kelleher K. Lawrence-Henderson R.F. Upeslacis E. Yao J. Narula J. LaVallie E.R. Fernandez D.R. Buetow B.S. Rosfjord E. Bloom L. King L.E. Tchistiakova L. Nguyen A. Sapra P. A novel GUCY2C-CD3 T-Cell engaging bispecific construct (PF-07062119) for the treatment of gastrointestinal cancers. Clin. Cancer Res. 2020 26 9 2188 2202 10.1158/1078‑0432.CCR‑19‑3275 31996389
    [Google Scholar]
  121. Lakins M.A. Koers A. Giambalvo R. Munoz-Olaya J. Hughes R. Goodman E. Marshall S. Wollerton F. Batey S. Gliddon D. Tuna M. Brewis N. FS222, a CD137/PD-L1 tetravalent bispecific antibody, exhibits low toxicity and antitumor activity in colorectal cancer models. Clin. Cancer Res. 2020 26 15 4154 4167 10.1158/1078‑0432.CCR‑19‑2958 32345647
    [Google Scholar]
  122. Tabernero J. Melero I. Ros W. Argiles G. Marabelle A. Rodriguez-Ruiz M.E. Albanell J. Calvo E. Moreno V. Cleary J.M. Eder J.P. Karanikas V. Bouseida S. Sandoval F. Sabanes D. Sreckovic S. Hurwitz H. Paz-Ares L.G. Saro Suarez J.M. Segal N.H. Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC). J. Clin. Oncol. 2017 35 15 Suppl. 3002 3002 10.1200/JCO.2017.35.15_Suppl.3002
    [Google Scholar]
  123. Magee M.S. Abraham T.S. Baybutt T.R. Flickinger J.C. Ridge N.A. Marszalowicz G.P. Prajapati P. Hersperger A.R. Waldman S.A. Snook A.E. Human GUCY2C-Targeted chimeric antigen receptor (CAR)-Expressing T cells eliminate colorectal cancer metastases. Cancer Immunol. Res. 2018 6 5 509 516 10.1158/2326‑6066.CIR‑16‑0362 29615399
    [Google Scholar]
  124. Hombach A.A. Geumann U. Günther C. Hermann F.G. Abken H. IL7-IL12 engineered mesenchymal stem cells (MSCs) improve A caR T cell attack against colorectal cancer cells. Cells 2020 9 4 873 10.3390/cells9040873 32260097
    [Google Scholar]
  125. PolyPEPI1018 vaccine and CDx for the treatment of metastatic colorectal cancer (OBERTO) 2022 Available from: https://clinicaltrials.gov/study/NCT03391232?tab=results
  126. Hubbard J.M. Tőke E.R. Moretto R. Graham R.P. Youssoufian H. Lőrincz O. Molnár L. Csiszovszki Z. Mitchell J.L. Wessling J. Tóth J. Cremolini C. Safety and activity of polypepi1018 combined with maintenance therapy in metastatic colorectal cancer: An open-label, multicenter, phase ib study. Clin. Cancer Res. 2022 28 13 2818 2829 10.1158/1078‑0432.CCR‑22‑0112 35472243
    [Google Scholar]
  127. Cremolini C. Schirripa M. Antoniotti C. Moretto R. Salvatore L. Masi G. Falcone A. Loupakis F. First-line chemotherapy for mCRC—a review and evidence-based algorithm. Nat. Rev. Clin. Oncol. 2015 12 10 607 619 10.1038/nrclinonc.2015.129 26215044
    [Google Scholar]
  128. Battaglin F. Puccini A. Intini R. Schirripa M. Ferro A. Bergamo F. Lonardi S. Zagonel V. Lenz H.J. Loupakis F. The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Rev. Anticancer Ther. 2018 18 3 251 266 10.1080/14737140.2018.1428092 29338550
    [Google Scholar]
  129. Cheng Y.D. Yang H. Chen G.Q. Zhang Z.C. Molecularly targeted drugs for metastatic colorectal cancer. Drug Des. Devel. Ther. 2013 7 1315 1322 24204124
    [Google Scholar]
  130. Bawa R. Szebeni J. Webster T.J. Audette G.F.,Eds Immune Aspects of Biopharmaceuticals and Nanomedicines. 1st ed Singapore Jenny Stanford Publishing 2019 10.1201/b22372
    [Google Scholar]
  131. Hallin J. Engstrom L.D. Hargis L. Calinisan A. Aranda R. Briere D.M. Sudhakar N. Bowcut V. Baer B.R. Ballard J.A. Burkard M.R. Fell J.B. Fischer J.P. Vigers G.P. Xue Y. Gatto S. Fernandez-Banet J. Pavlicek A. Velastagui K. Chao R.C. Barton J. Pierobon M. Baldelli E. Patricoin E.F. Cassidy D.P. Marx M.A. Rybkin I.I. Johnson M.L. Ou S.H.I. Lito P. Papadopoulos K.P. Jänne P.A. Olson P. Christensen J.G. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of kras-mutant cancers in mouse models and patients. Cancer Discov. 2020 10 1 54 71 10.1158/2159‑8290.CD‑19‑1167 31658955
    [Google Scholar]
  132. Wu X. Gu Z. Chen Y. Chen B. Chen W. Weng L. Liu X. Application of PD-1 blockade in cancer immunotherapy. Comput. Struct. Biotechnol. J. 2019 17 661 674 10.1016/j.csbj.2019.03.006 31205619
    [Google Scholar]
  133. Chi X. Yang P. Zhang E. Gu J. Xu H. Li M. Gao X. Li X. Zhang Y. Xu H. Hu J. Significantly increased anti‐tumor activity of carcinoembryonic antigen‐specific chimeric antigen receptor T cells in combination with recombinant human IL‐12. Cancer Med. 2019 8 10 4753 4765 10.1002/cam4.2361 31237116
    [Google Scholar]
  134. Wang Y. Chen M. Wu Z. Tong C. Dai H. Guo Y. Liu Y. Huang J. Lv H. Luo C. Feng K. Yang Q. Li X. Han W. CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial. OncoImmunology 2018 7 7 1440169 10.1080/2162402X.2018.1440169 29900044
    [Google Scholar]
/content/journals/cpb/10.2174/0113892010390001251014113106
Loading
Biological Therapies for Metastatic Colorectal Cancer: Literature Review
Bentham Science Publishers ; https://doi.org/10.2174/0113892010390001251014113106
/content/journals/cpb/10.2174/0113892010390001251014113106
/content/journals/cpb/10.2174/0113892010390001251014113106
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Colorectal cancer ; monoclonal antibodies ; targeted therapy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test